33 terminated. 33 Phase 2, 4 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 33 | Terminated 33 |
| Phase 1 | 4 | Terminated 4 |
| Phase 3 | 2 | Terminated 2 |
Follow Psoriasis: new trials by email Literature Review of Psoriasis trials Research Report on Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis TQH2929 Injections, TQH2929 Placebo - Generalized Pustular Psoriasis | Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 36 | 2026-03-19 | 2026-08-03 |
| TYK2 Inhibition in Paradoxical Psoriasis Deucravacitinib - Psoriasis | Phase 2 / Phase 3 | Terminated | Prof Curdin Conrad | 2 | 2024-06-20 | 2025-04-02 |
| VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA) Dose A VTX958, Dose B VTX958, Placebo - Psoriatic Arthritis | Phase 2 | Terminated | Ventyx Biosciences, Inc | 205 | 2023-01-31 | 2024-12-27 |
| Psoriatic Arthritis Study of Izokibep Izokibep, Placebo to izokibep - Psoriatic Arthritis | Phase 2 / Phase 3 | Terminated | ACELYRIN Inc. | 351 | 2022-11-21 | 2025-05-23 |
| VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis VTX958 Dose A, VTX958 Dose B, VTX958 Dose C - Psoriasis | Phase 2 | Terminated | Ventyx Biosciences, Inc | 222 | 2022-11-17 | 2024-09-19 |
| Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis ATI-450, Placebo Oral Tablet - Psoriatic Arthritis | Phase 2 | Terminated | Aclaris Therapeutics, Inc. | 47 | 2022-07-12 | 2024-11-27 |
| Impact of Cannabis on Pain and Inflammation Among Patients With Rheumatoid or Psoriatic Arthritis Cannabis: placebo and medium THC/medium CBD - Rheumatoid Arthritis, Psoriatic Arthritis | Phase 2 | Terminated | Brown University | 3 | 2022-05-18 | 2025-04-01 |
| A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP) RIST4721, Placebo - Palmoplantar Pustulosis | Phase 2 | Terminated | Aristea Therapeutics, Inc. | 79 | 2022-01-05 | 2023-06-29 |
| A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis Cedirogant, Placebo - Psoriasis | Phase 2 | Terminated | AbbVie | 156 | 2021-11-16 | 2023-11-29 |
| A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab Spesolimab - Palmoplantar Pustulosis | Phase 2 | Terminated | Boehringer Ingelheim | 108 | 2020-09-04 | 2025-10-20 |
| A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is BI 730357, Placebo to match BI 730357 - Psoriasis | Phase 2 | Terminated | Boehringer Ingelheim | 165 | 2019-03-18 | 2022-11-18 |
| Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis Icotinib hydrochloride cream, Placebo cream - Mild to Moderate Psoriasis | Phase 2 | Terminated | Betta Pharmaceuticals Co., Ltd. | 136 | 2017-11-29 | 2018-11-14 |
| Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis JTE-051, Placebo - Plaque Psoriasis, Skin Diseases | Phase 2 | Terminated | Akros Pharma Inc. | 13 | 2017-11-10 | 2021-08-06 |
| A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis BMS-986251, Placebo - Rheumatoid Arthritis, Psoriasis | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 38 | 2017-11-02 | 2019-10-21 |
| 99mTc-rhAnnexin V-128 in Diagnosis of Spondyloarthritis rhAnnexin V-128 - Spondyloarthritis | Phase 2 | Terminated | Advanced Accelerator Applications | 5 | 2017-09-18 | 2019-12-13 |
| An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis. filgotinib - Psoriatic Arthritis | Phase 2 | Terminated | Lakefront Biotherapeutics NV | 122 | 2017-07-26 | 2022-04-21 |
| Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06 DFD06 - Psoriasis | Phase 2 | Terminated | Primus Pharmaceuticals | 22 | 2017-05-02 | 2024-03-07 |
| A Phase 2, Multicenter Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197 ABT-122 - Psoriatic Arthritis | Phase 2 | Terminated | AbbVie | 168 | 2015-10-01 | 2016-06-17 |
| Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis PF-04965842, Placebo - Plaque Psoriasis | Phase 2 | Terminated | Pfizer | 59 | 2014-11-01 | 2016-10-05 |
| AMG 827 in Subjects With Psoriatic Arthritis AMG 827 140, Placebo, AMG 827 280 - Psoriatic Arthritis | Phase 2 | Terminated | Bausch Health Americas, Inc. | 168 | 2011-10-01 | 2020-08-27 |
Showing 20 of 33. Sign in to see all of them.
Arthritis, Psoriatic (11) · Arthritis (3) · Arthritis, Rheumatoid (2) · Dermatitis, Atopic (2) · Inflammatory Bowel Diseases (2) · Skin Diseases (2) · Spondylitis, Ankylosing (2) · Alopecia (1) · Eczema (1) · Lymphoma, Follicular (1) · Lymphoma, T-Cell, Cutaneous (1) · Musculoskeletal Diseases (1) · Mycosis Fungoides (1) · Non-alcoholic Fatty Liver Disease (1)
Skin Diseases, Papulosquamous (33) · Skin and Connective Tissue Diseases (33) · Skin Diseases (31) · Bone Diseases (12) · Joint Diseases (12) · Spinal Diseases (12) · Spondylitis (12) · Musculoskeletal Diseases (11) · Spondylarthritis (11) · Spondylarthropathies (11) · Arthritis (9) · Immune System Diseases (5) · Ankylosis (2) · Autoimmune Diseases (2)
teplizumab (2) · 5-(9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro(4,4)non-7-ylmethyl)-3-thiophenecarboxylic acid (1) · ABT-122 (1) · Abatacept (1) · Adalimumab (1) · Clobetasol (1) · Folic Acid (1) · GLPG0634 (1) · Penicillin G Benzathine (1) · Pyridoxine (1) · Vitamin B 12 (1) · Vitamin B 6 (1) · abrocitinib (1) · brodalumab (1) · deucravacitinib (1)
Bristol-Myers Squibb (3) · AbbVie (2) · Bausch Health Americas, Inc. (2) · Boehringer Ingelheim (2) · Ventyx Biosciences, Inc (2) · ACELYRIN Inc. (1) · Aclaris Therapeutics, Inc. (1) · Advanced Accelerator Applications (1) · Akros Pharma Inc. (1) · Aristea Therapeutics, Inc. (1) · Betta Pharmaceuticals Co., Ltd. (1) · Brown University (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Eli Lilly and Company (1) · Lakefront Biotherapeutics NV (1)
United States (23) · Canada (12) · Poland (8) · Germany (7) · Czechia (6) · Hungary (5) · Spain (5) · Australia (4) · Bulgaria (4) · Belgium (3) · France (3) · China (2) · Italy (2) · Japan (2) · Netherlands (2)
Alice B Gottlieb, MD, PhD (1) · Curdin Conrad, Professor (1) · Elias Rosenberg, MD (1) · Elizabeth Aston, PhD (1) · Heikki T Mansikka, MD (1) · John J Voorhees, MD (1) · Luigi Naldi, dermatology (1) · Marcus Clark, MD (1) · Matt Cascino, MD (1) · Melissa Magliocco, MD (1) · Min Zheng, PHD (1)
PMID 18645136, PMID 21128258, PMID 24434748, PMID 26773108, PMID 30032191, PMID 31493163, PMID 32207067, PMID 35061234, PMID 35137002, PMID 35342978, PMID 36919398, PMID 38896380, PMID 39848568
2017 (2), 2014 (1), 2018 (1), P20GM130414 (1)